IMPACT OF VICOPROFEN ON PLASMA PROENKEPHALIN PEPTIDE F... : Medicine & Science in Sports & Exercise (original) (raw)

B160 FREE COMMUNICATION/POSTER ENDOCRINOLOGY

IMPACT OF VICOPROFEN ON PLASMA PROENKEPHALIN PEPTIDE F CONCENTRATIONS AFTER

Kraemer, W J. FACSM1; French, D N.1; Gomez, A L.1; Rubin, M R.1; Scheett, T P.1; Volek, J S.1; VanHeest, J L.1; Ratamess, N A.1; Sharman, M J.1; Stoppani, J1; Hoffman, J R. FACSM1; Maresh, C M. FACSM1

1The Human Performance Laboratory, University of Connecticut, Storrs, CT

Free

Peptide F [preproenkephalin (107–140)] has been shown to have stress-induced opiate-like activities with both analgesic and immune modulation characteristics.

PURPOSE:

The purpose of this study was to determine the effects of Vicopofen (hydrocodone bitartrate 7.5 mg with ibuprofen 200mg), ibuprofen (200mg) and placebo on proenkephalin Peptide F following muscle damage induced via repeated eccentric muscle actions (120% of Concentric 1 RM).

METHODS:

Thirty-six healthy men (22.7 ± 0.9 yrs, 78.2 ± 2.5 kg, 178.5 ± 6.8 cm) underwent baseline performance testing and blood sampling and 24 hrs after the muscle damage subjects were randomized to one of three experimental groups (Vicoprofen, (VIC) Ibuprofen (IBU), or placebo (P) prior to post-exercise testing. Following this performance testing session subjects were instructed in taking the medication. Subjects participated in rigorous post-exercise testing every 24 hours over four more days.

RESULTS:

Area under the curve analyses demonstrated that VIC had significantly (P < 0.05) higher concentrations of Peptide F than the IBU or P groups. VIC and IBU had significantly higher values for Peptide F on recovery days 1 and 2 compared to controls, while on days 3 and 4 VIC values were significantly higher than both IBU and P.

CONCLUSION:

The ability of the VIC to maintain higher endogenous concentrations of Peptide F over a physically active recovery period suggests that Peptide F may be involved in the mediation of some of the pharmaceutical effects related to recovery from eccentrically-induced muscle damage. Supported in part by a grant from Knoll Pharmaceutical Co., Mount Olive, NJ.